The project helped create and expand a competitive market for second-line ARVs. The number of suppliers, particularly generic manufacturers, increased, better formulations came into the market, and prices decreased to a level more accessible to low-income countries. The prices for second-line ARVs decreased by between 15 and 70 percent from the start of the project. The project also had beneficial indirect effects on the use of tenofovir as a more cost-effective first-line treatment. All 25 target countries were able to transition to alternative funding to procure second-line HIV drugs by the end of the project.